ASCO GU 2018: Adjuvant radiotherapy and chemotherapy in node-positive prostate cancer

The use adjuvant treatment for patients with high risk or node-positive prostate cancer patients remains controversial despite level 1 evidence demonstrating a benefit. The controversy revolves around the risk of over treatment in addition to the lack of evidence demonstrating the superiority of adjuvant over early salvage therapy.
Uro Today